Press Releases
-
2021
- Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding | Apr-21
- Atriva Therapeutics kann dank Fördermitteln COVID-19-Medikament schneller entwickeln | Apr-21
- Atriva Therapeutics Announces Changes to Management in COVID-19 | Apr-13
- Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19 | Apr-13
- Atriva Therapeutics Announces Changes to Advisory Board | Jan-20
- Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin | Jan-05
-
2020
- Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente | Dec-02
- Germany: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment | Oct-20
- Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan | Aug-11
- Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target | Jun-30
- Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study | May-28
- Major conferences in San Francisco | Jan-09
-
2019
- Atriva Therapeutics Reports Results of ATR-002 Phase I Clinical Trial | Nov-08
- Atriva Therapeutics to present at the BIO-Europe in Hamburg | Oct-31
- Atriva Therapeutics takes part in four conferences in the upcoming months | Sep-03
- Atriva Therapeutics Receives EU Award for Biomarker Validation | Jul-17
- Atriva Therapeutics Starts Clinical Development of novel Host-Targeting Antiviral ATR-002 Against Influenza | Jun-03
- Wirtschaftswoche: 1,25 Mio. Euro für den Kampf gegen Viren | Jan-07
- Atriva Therapeutics announces first closing of series A financing round | Jan-02
-
2017
- Atriva adds Dr. Christian Wallasch to its executive management team. | Dec-03
- New article published in "Platform Life Sciences" presenting ATRIVA approach | Nov-20
- Invited keynote lecture on ATRIVAs antiviral MEK inhibitor technology presented at the Annual Meeting of the German Pharmaceutical Society (DPhG) | Nov-20
- Atriva reaches a development milestone and receives an additional tranche of running seed financing to develop its influenza therapeutic to clinical stage | Nov-20
- New Image Video of ATRIVA available! | Nov-20
- ATRIVA scientists present MEK inhibitor technology at International Conference of Antiviral Research in Atlanta | Nov-20
- Interview with ATRIVA CEO during BIO-Europe Spring(R) 2017 | Nov-20
- New paper published about anti-influenza activity of CI-1040 | Nov-20
- Host with the most: Targeting host cells instead of pathogens to fight infectious disease | Nov-20
- Atriva receives seed financing to develop its next generation influenza therapeutic | Nov-20
- Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases | Nov-19
-
2016
-
2015